CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society’s 41st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026.
“The launch of the Bi-lateral System further expands our proprietary technology platform to enable a direct posterior approach for personalized spine fusion,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “The Bi-lateral System is optimized to support planned three-dimensional correction of the spine with maximal surface area contact.”
“Since its initial release, aprevo® has established itself as a valuable tool in my surgical armamentarium, allowing me to achieve a new level of patient specificity in my procedures,” stated Dr. CJ Kleck of University of Colorado. “I have been impressed with the results achieved and look forward to utilizing the technology when appropriate for my patients.”
“I see great potential in this system for patients who may benefit from a posterior approach,” added Dr. Joshua Bakhsheshian of Mayo Clinic, who will be sharing his clinical experience with aprevo® Bi-lateral at NASS. “Carlsmed’s technology has enabled a greater level of patient specificity in preoperative planning, with the potential to contribute to improved long-term patient outcomes.”
Carlsmed’s Bi-lateral System leverages the Company’s technology platform, which combines proprietary AI-enabled software and clinical intelligence to deliver surgeon-specific three-dimensional surgical plans and patient-specific fusion devices across a broad range of spinal pathologies.
About Carlsmed
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects, including statements about the potential of Carlsmed’s products, statements regarding patient outcomes and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.
Investor Relations
IR@Carlsmed.com